Q-omics provides the consensus-scored GLYCTK-AS1 profile across patient tissues and cancer cell-line models. GLYCTK-AS1 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, GLYCTK-AS1 is differentially expressed in 8, with the highest sampling consensus in LIHC. Additionally, GLYCTK-AS1 RNA expression shows 19,019 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UCEC, LIHC, and TGCT as cancer lineages where GLYCTK-AS1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GLYCTK-AS1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GLYCTK-AS1 survival associations across molecular data types. GLYCTK-AS1 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GLYCTK-AS1 RNA expression–survival associations across cancer types. High GLYCTK-AS1 expression shows unfavorable associations in KIRC and PCPG, but favorable associations in UCEC, LGG, HNSC and BRCA. The UCEC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .003). Together, the overview and detailed table identify UCEC as the clearest survival context for GLYCTK-AS1 RNA expression.
This table summarizes GLYCTK-AS1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for GLYCTK-AS1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GLYCTK-AS1 shows lower tumor expression in LUSC and higher tumor expression in LIHC, COAD, STAD, KICH and BLCA. The LIHC box plot shows higher GLYCTK-AS1 RNA expression in tumor versus normal tissue (log2 FC = +0.125, t-test p < 0.001).
This table shows molecular features associated with GLYCTK-AS1 in patient tissues and cancer cell lines. In patient samples, GLYCTK-AS1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
